文献速递炎症性肠病

英夫利西单抗再治疗克罗恩病的疗效与安全性:GETAID的多中心前瞻性观察队列(REGAIN)研究

Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.
PubMed 文献 · Am J Gastroenterol · 2022-06-02

这项多中心前瞻性观察队列纳入69例临床和客观活动期克罗恩病成人患者,在停用英夫利西单抗至少6个月后因继发性失应答或不耐受而再治疗,第26周35%达到主要终点,既往失应答者与不耐受者临床缓解率无显著差异,早期检出抗药物抗体可预测再治疗失败和输注反应。

要点

  • 第26周24/69例(35%)达到主要终点,即CDAI<150且未停用英夫利西单抗、未用激素、手术或其他生物制剂。
  • 既往失应答者(n=48)与不耐受者(n=21)第26周临床缓解率分别为35%和33%,无显著差异(P=0.87)。
  • 27例记录32次急性输注反应,其中20例因此停用英夫利西单抗;第4周检出抗药物抗体可预测第26周治疗失败或输注反应。

核心结论

  • 在这项首个前瞻性队列研究中,英夫利西单抗再治疗对三分之一的克罗恩病患者安全有效,与既往停药原因无关。
  • 早期检出抗药物抗体可预测后续英夫利西单抗再治疗失败和输注反应。

研究设计与样本

  • 前瞻性多中心观察队列研究,纳入临床(CDAI>150)和客观活动期管腔型克罗恩病成人患者。
  • 患者在停用英夫利西单抗至少6个月后再治疗,初始停药原因为继发性失应答或英夫利西单抗不耐受。
  • 再治疗方案为第0、4、8周给予3次英夫利西单抗输注,并系统预用药。
  • 共69例纳入分析,其中既往失应答48例、不耐受21例。

主要发现

  • 第26周24例(35%)达到主要终点。
  • 既往失应答者(n=48)与不耐受者(n=21)第26周临床缓解率分别为35%和33%,无显著差异(P=0.87)。
  • 27例患者记录32次急性输注反应,导致20例停用英夫利西单抗。
  • 基线药代动力学特征均不能预测结局,但第4周检出抗药物抗体阳性可预测第26周英夫利西单抗治疗失败或输注反应。

关键数值与推荐

  • 主要终点为第26周英夫利西单抗再治疗有效,定义为CDAI<150且未停用英夫利西单抗、未使用糖皮质激素、未手术或未使用其他生物制剂。
  • 临床活动期定义为CDAI>150。
  • 再治疗方案为第0、4、8周给予3次英夫利西单抗输注,并系统预用药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The objective of this study was to describe the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after stopping for loss of response or intolerance. METHODS: We conducted a prospective multicenter observational cohort study including adult patients with clinically (CD Activity Index >150) and objectively active luminal CD in whom IFX was reintroduced after at least 6 months of discontinuation. The reasons for the initial discontinuation could be a secondary loss of response or IFX intolerance. The reintroduction schedule included 3 IFX infusions at weeks 0, 4, and 8, after a systematic premedication. The primary end point was the efficacy of IFX retreatment at week 26 defined by a CD Activity Index of <150 in the absence of IFX discontinuation or use of corticosteroids, surgery, or other biologic. RESULTS: At week 26, 24 patients (35%) among the 69 analyzed reached the primary end point. No significant difference was observed between rates of clinical remission at week 26 in patients with prior LOR (n = 48) and those with IFX intolerance (n = 21) (35% and 33%, P = 0.87, respectively). Thirty-two acute infusion reactions were recorded in 27 patients, leading to withdrawal of IFX in 20 patients. No pharmacokinetic characteristic at baseline but detection of positive anti-drug antibodies at week 4 was predictive of IFX failure or infusion reaction at week 26. DISCUSSION: In this first prospective cohort study, IFX retreatment was safe and effective in one-third of the patients with CD, regardless the reason of prior discontinuation. Early detection of anti-drug antibodies can predict subsequent IFX reintroduction failure and infusion reactions.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Boschetti G, Nachury M, Laharie D, et al. Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID. Am J Gastroenterol. 2022. PMID: 35973142. doi:10.14309/ajg.0000000000001842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。